186 related articles for article (PubMed ID: 35811835)
1. Systematic literature review on the implicit factors influencing the HTA deliberative process in Europe.
Monleón C; Späth HM; Crespo C; Dussart C; Toumi M
J Mark Access Health Policy; 2022; 10(1):2094047. PubMed ID: 35811835
[TBL] [Abstract][Full Text] [Related]
2. Implicit factors influencing the HTA deliberative processes in 5 European countries: results from a mixed-methods research.
Monleón C; Martin-Späth H; Crespo C; Dussart C; Toumi M
Health Policy Open; 2023 Dec; 5():100109. PubMed ID: 38073709
[TBL] [Abstract][Full Text] [Related]
3. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
[TBL] [Abstract][Full Text] [Related]
4. Deliberative processes in health technology assessment of medicines: the case of Spain.
Pinilla-Dominguez P; Pinilla-Dominguez J
Int J Technol Assess Health Care; 2023 Jul; 39(1):e50. PubMed ID: 37403252
[TBL] [Abstract][Full Text] [Related]
5. Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force.
Oortwijn W; Husereau D; Abelson J; Barasa E; Bayani DD; Santos VC; Culyer A; Facey K; Grainger D; Kieslich K; Ollendorf D; Pichon-Riviere A; Sandman L; Strammiello V; Teerawattananon Y
Int J Technol Assess Health Care; 2022 Jun; 38(1):e37. PubMed ID: 35656641
[TBL] [Abstract][Full Text] [Related]
6. Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force.
Oortwijn W; Husereau D; Abelson J; Barasa E; Bayani DD; Canuto Santos V; Culyer A; Facey K; Grainger D; Kieslich K; Ollendorf D; Pichon-Riviere A; Sandman L; Strammiello V; Teerawattananon Y
Value Health; 2022 Jun; 25(6):869-886. PubMed ID: 35667778
[TBL] [Abstract][Full Text] [Related]
7. Towards Integrated Health Technology Assessment for Improving Decision Making in Selected Countries.
Oortwijn W; Determann D; Schiffers K; Tan SS; van der Tuin J
Value Health; 2017 Sep; 20(8):1121-1130. PubMed ID: 28964444
[TBL] [Abstract][Full Text] [Related]
8. The impact of HTA reports on health policy: a systematic review.
Gerhardus A; Dintsios CM
GMS Health Technol Assess; 2005 Nov; 1():Doc02. PubMed ID: 21289923
[TBL] [Abstract][Full Text] [Related]
9. Evidence-Informed Deliberative Processes for Health Benefit Package Design - Part II: A Practical Guide.
Oortwijn W; Jansen M; Baltussen R
Int J Health Policy Manag; 2022 Oct; 11(10):2327-2336. PubMed ID: 34923809
[TBL] [Abstract][Full Text] [Related]
10. Use of Evidence-Informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe.
Oortwijn W; Jansen M; Baltussen R
Int J Health Policy Manag; 2020 Jan; 9(1):27-33. PubMed ID: 31902192
[TBL] [Abstract][Full Text] [Related]
11. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.
Angelis A; Lange A; Kanavos P
Eur J Health Econ; 2018 Jan; 19(1):123-152. PubMed ID: 28303438
[TBL] [Abstract][Full Text] [Related]
12. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
Nicod E
Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
[TBL] [Abstract][Full Text] [Related]
13. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
14. Patient advocacy group involvement in health technology assessments: an observational study.
Single A; Cabrera A; Fifer S; Tsai J; Paik JY; Hope P
Res Involv Engagem; 2021 Nov; 7(1):83. PubMed ID: 34823610
[TBL] [Abstract][Full Text] [Related]
15. Principles for deliberative processes in health technology assessment.
Bond K; Stiffell R; Ollendorf DA
Int J Technol Assess Health Care; 2020 Aug; ():1-8. PubMed ID: 32746954
[TBL] [Abstract][Full Text] [Related]
16. Addressing Health System Values in Health Technology Assessment: The Use of Evidence-Informed Deliberative Processes.
Oortwijn W; Klein P
Int J Technol Assess Health Care; 2019; 35(2):82-84. PubMed ID: 30957730
[TBL] [Abstract][Full Text] [Related]
17. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
18. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
Akehurst RL; Abadie E; Renaudin N; Sarkozy F
Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
[TBL] [Abstract][Full Text] [Related]
19. Evidence-Informed Deliberative Processes for HTA Around the Globe: Exploring the Next Frontiers of HTA and Best Practices Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe".
Gopinathan U; Ottersen T; Cyr PR; Chalkidou K
Int J Health Policy Manag; 2021 Mar; 10(4):232-236. PubMed ID: 32772012
[TBL] [Abstract][Full Text] [Related]
20. Value Assessment Frameworks for HTA Agencies: The Organization of Evidence-Informed Deliberative Processes.
Baltussen R; Jansen MPM; Bijlmakers L; Grutters J; Kluytmans A; Reuzel RP; Tummers M; der Wilt GJV
Value Health; 2017 Feb; 20(2):256-260. PubMed ID: 28237205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
